Europe is becoming less competitive in the advanced therapy space, something that is reflected in the number of EU ATMP marketing authorization withdrawals, speakers said at an event organized by the Alliance for Regenerative Medicine.

Immunotherapies for esophageal cancer from BMS and MSD are among the medicines that Scotland’s health technology appraisal body has recommended for use on the National Health system.

Indication-based pricing and tackling complications caused by competition law could help the UK catch up with other countries when it comes to market access for combination therapies.

Orchard Therapeutics says it is confident in the success of its gene therapy for MLD, which has secured the highest possible benefit rating from the German authorities.

Some measures aimed at reducing medicine prices in Canada have been dropped, to the relief of the pharmaceutical industry.

New regulations on health technology assessments pose both a threat and an opportunity for getting advanced therapies to market in Europe, while pay-for-performance deals can solve the problem of high up-front payments, said speakers at an event organized by the Alliance for Regenerative Medicine.